Nivolumab patent expiration date?

There isn’t a single “Nivolumab patent expiration date.” Nivolumab (Opdivo) is protected by multiple patent families in multiple jurisdictions (US, EU, JP, etc.), covering things like the antibody itself (composition of matter), methods of use, formulations, and production methods. Each patent family has its own expiry date, often with term extensions or other regulatory protections that can shift the effective date.

If you want precise dates, I can help, but I’ll need:
- Which jurisdiction(s) you care about (e.g., United States, European Union, Japan, etc.), and
- Which type of patent you’re interested in (composition-of-matter/antibody itself, method of use, formulation, manufacturing).

A quick path to get exact dates:
- Tell me the jurisdiction and patent family (or I can look up the main nivolumab patent families for you).
- I’ll list the expiry dates (and any term adjustments or data-exclusivity considerations that might affect market entry).

Note: In addition to patent expiry, regulatory data exclusivity for biologics (e.g., in the US, a 12-year data exclusivity for a new biologic) can influence when competitors can obtain approval, even after patent expiry.